fi en false false
UCTCYBO VanEck Bionic Engineering UCITS ETF Please read important disclosure Close important disclosure true
Marketing Communication
CYBO

Bionic ETF
VanEck Bionic Engineering UCITS ETF

Marketing Communication
CYBO

Bionic ETF
VanEck Bionic Engineering UCITS ETF

ISIN: IE0005TF96I9 copy-icon
research-link-icon Why invest in a Bionic ETF?
Why invest
Documents
research-link-icon Fact Sheet
research-link-icon KID
research-link-icon Prospectus

Fund Description

As the global population ages, so does the demand for biologically-inspired systems that improve the quality of later life. VanEck’s Bionic Engineering ETF tracks the performance of the portfolio of innovative companies delivering medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue.

  • NAV
    $21.33

    as of 03 Dec 2024
  • YTD RETURNS
    3.05%

    as of 03 Dec 2024
  • Total Net Assets
    $5.1 million

    as of 03 Dec 2024
  • Total Expense Ratio
    0.55%
  • Inception Date
    02 Dec 2022
  • SFDR Classification
    Article 9
research-link-icon Why invest in a Bionic ETF?
Why invest
Documents
research-link-icon Fact Sheet
research-link-icon KID
research-link-icon Prospectus

Overview

Fund Description

As the global population ages, so does the demand for biologically-inspired systems that improve the quality of later life. VanEck’s Bionic Engineering ETF tracks the performance of the portfolio of innovative companies delivering medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue.

  • Invest in companies at the forefront of improving quality of life for the world’s ageing population
  • Gain diversified exposure to companies involved in medical implants and bionic enhancements for chronic diseases and functional impairments
  • Access companies earning at least half their revenues from bionic engineering-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Main Risk Factors: Equity market risk, industry or sector concentration risk, Liquidity Risks. Please refer to the

KID

and the Prospectus for other important information before investing.



Underlying Index

MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)

Fund Highlights

  • Invest in companies at the forefront of improving quality of life for the world’s ageing population
  • Gain diversified exposure to companies involved in medical implants and bionic enhancements for chronic diseases and functional impairments
  • Access companies earning at least half their revenues from bionic engineering-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk Factors: Equity market risk, industry or sector concentration risk, Liquidity Risks. Please refer to the

KID

and the Prospectus for other important information before investing.



Underlying Index

MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)

Capital Markets

VanEck partners with esteemed market makers to ensure the availability of our products for trading on the mentioned stock exchanges. Our Capital Markets team is committed to continuously monitoring and assessing spreads, sizes, and prices to ensure optimal trading conditions for our clients. Furthermore, VanEck ETFs are available on various trading platforms, and we collaborate with a wider range of reputable Authorized Participants (APs) to promote an efficient and fair trading environment. For more information about our APs and to contact our Capital Markets team, please visit factsheet capital markets.pdf

Performance

Holdings

Portfolio

Documents

Index

Index Description

The MVIS Global Bionic Healthcare ESG Index is a global index that tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, or prosthesis.

Index Key Points

Underlying Index
MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)

The Index Composition:

The MVIS®Global Bionic Healthcare ESG Index (MVBIONTR) tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, or prosthesis. MVBION covers at least 90% of the investable universe.

Companies initially eligible for inclusion in Index:


  • Companies involved in bionic healthcare industries. This includes companies with at least 50% (25% forcurrent components) of their revenues from the following sub-themes:
    Medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue. The index does not include companies involved in implantable or wearable devices or materials used only for cosmetic purposes
  • Companies with at least 50% of their revenues from sectors defined above
  • Market capitalization greater than $150 million
  • Three-month average daily turnover greater than $1 million
  • Minimum trading volume of 250,000 shares each month over last 6 months
  • Company weightings are capped at 10%.


Index provider:

MVIS

Awards

Main Risks

Main Risk Factors of a Bionic ETF

  • Industry or Sector Concentration Risk
  • Equity Market Risk
  • Liquidity Risks
Icon

The Fund’s assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.

Icon

The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.

Icon

Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.

For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on www.vaneck.com.